1. Vitamin D Related/Nuclear Receptor
  2. Estrogen Receptor/ERR
  3. 2092925-89-6

2092925-89-6

Palazestrant Chemical Structure

2092925-89-6

Chemical Structure

  • Palazestrant
  • Synonym(s): OP-1250
  • CAS No: 2092925-89-6
    Formula: C28H36FN3O
    Molecular Weight: 449.60
  • IUPAC Name: (1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-1-(4-((1-propylazetidin-3-yl)oxy)phenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
  • InChIKey: LBSFUBLFDCAEKV-XHCCPWGMSA-N
  • SMILES: CC(C)(F)CN1[C@H](C2=CC=C(C=C2)OC3CN(C3)CCC)C4=C(C[C@H]1C)C5=CC=CC=C5N4

Biological Activity: Palazestrant is an antiestrogen and antineoplastic agent. Palazestrant can completely inhibit the activity of 17b-estradiol (E2) with IC50 value of 6.4 nM, and inhibit the proliferation of MCF7 and CAMA-1 cells with IC50 value of 1.4-1.6 nM. Palazestrant can inhibit ER+/HER2+ cancer[1][2][3].

Cat. No. Product Name Purity Description
HY-148789 Palazestrant 98.96% Palazestrant is an antiestrogen and antineoplastic agent. Palazestrant can completely inhibit the activity of 17b-estradiol (E2) with IC50 value of 6.4 nM, and inhibit the proliferation of MCF7 and CAMA-1 cells with IC50 value of 1.4-1.6 nM. Palazestrant can inhibit ER+/HER2+ cancer.

References

Keywords:

Palazestrant